ATE551060T1 - Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen - Google Patents
Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungenInfo
- Publication number
- ATE551060T1 ATE551060T1 AT05804888T AT05804888T ATE551060T1 AT E551060 T1 ATE551060 T1 AT E551060T1 AT 05804888 T AT05804888 T AT 05804888T AT 05804888 T AT05804888 T AT 05804888T AT E551060 T1 ATE551060 T1 AT E551060T1
- Authority
- AT
- Austria
- Prior art keywords
- signaling inhibitor
- compositions
- methods
- neovascular diseases
- trprs
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 101000640990 Arabidopsis thaliana Tryptophan-tRNA ligase, chloroplastic/mitochondrial Proteins 0.000 abstract 4
- 102000002501 Tryptophan-tRNA Ligase Human genes 0.000 abstract 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 230000011664 signaling Effects 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000964 angiostatic effect Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 230000006459 vascular development Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
- C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)
- C12Y601/01002—Tryptophan-tRNA ligase (6.1.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57715604P | 2004-06-04 | 2004-06-04 | |
| US58527304P | 2004-07-01 | 2004-07-01 | |
| US65580105P | 2005-02-24 | 2005-02-24 | |
| PCT/US2005/019800 WO2005117954A2 (en) | 2004-06-04 | 2005-06-06 | Compositions and methods for treatment of neovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551060T1 true ATE551060T1 (de) | 2012-04-15 |
Family
ID=35463352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05804888T ATE551060T1 (de) | 2004-06-04 | 2005-06-06 | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7528106B2 (de) |
| EP (3) | EP1765362B1 (de) |
| JP (1) | JP4943324B2 (de) |
| KR (1) | KR101224368B1 (de) |
| AT (1) | ATE551060T1 (de) |
| AU (1) | AU2005249586B2 (de) |
| CA (1) | CA2568750C (de) |
| DK (2) | DK1765362T3 (de) |
| ES (3) | ES2382661T3 (de) |
| MX (1) | MXPA06014092A (de) |
| PL (2) | PL2484365T3 (de) |
| PT (2) | PT1765362E (de) |
| WO (1) | WO2005117954A2 (de) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101224368B1 (ko) * | 2004-06-04 | 2013-01-22 | 더 스크립스 리서치 인스티튜트 | 혈관신생 질환 치료용 조성물 및 방법 |
| US8282921B2 (en) * | 2004-08-02 | 2012-10-09 | Paul Glidden | tRNA synthetase fragments |
| US20060024288A1 (en) * | 2004-08-02 | 2006-02-02 | Pfizer Inc. | tRNA synthetase fragments |
| RU2401124C2 (ru) * | 2005-02-24 | 2010-10-10 | Дзе Скриппс Рисерч Инститьют | Реваскуляризация ишемической ткани сетчатки и способ ее скрининга |
| ES2338400B1 (es) * | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
| US20100092434A1 (en) * | 2008-06-11 | 2010-04-15 | Atyr Pharma, Inc. | Thrombopoietic activity of tyrosyl-trna synthetase polypeptides |
| WO2009158649A1 (en) | 2008-06-26 | 2009-12-30 | Atyr Pharma, Inc. | Compositions and methods comprising glycyl-trna synthetases having non-canonical biological activities |
| WO2010099477A2 (en) | 2009-02-27 | 2010-09-02 | Atyr Pharma, Inc. | Polypeptide structural motifs associated with cell signaling activity |
| DK2408905T3 (en) | 2009-03-16 | 2017-08-28 | Pangu Biopharma Ltd | Compositions and Methods comprising Histidyl-tRNA Synthetase Splicing Variants with Non-Canonical Biological Activities |
| US20100235734A1 (en) * | 2009-03-16 | 2010-09-16 | Bas Ording | Methods and Graphical User Interfaces for Editing on a Multifunction Device with a Touch Screen Display |
| WO2010120509A2 (en) * | 2009-03-31 | 2010-10-21 | Atyr Pharma, Inc. | Compositions and methods comprising aspartyl-trna synthetases having non-canonical biological activities |
| US8828395B2 (en) | 2009-12-11 | 2014-09-09 | Atyr Pharma, Inc. | Antibodies that bind tyrosyl-tRNA synthetases |
| US20110150885A1 (en) * | 2009-12-11 | 2011-06-23 | Atyr Pharma, Inc. | Aminoacyl trna synthetases for modulating hematopoiesis |
| JP5819314B2 (ja) | 2009-12-11 | 2015-11-24 | エータイアー ファーマ， インコーポレイテッド | 炎症を調節するためのアミノアシルｔＲＮＡシンテターゼ |
| CN103118692A (zh) | 2010-04-26 | 2013-05-22 | Atyr医药公司 | 与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| JP6240500B2 (ja) | 2010-04-27 | 2017-11-29 | エータイアー ファーマ， インコーポレイテッド | スレオニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
| CA2797362C (en) | 2010-04-27 | 2020-12-08 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases |
| CN103097524B (zh) | 2010-04-28 | 2016-08-03 | Atyr医药公司 | 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| AU2011248457B2 (en) | 2010-04-29 | 2017-02-16 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases |
| US8986680B2 (en) | 2010-04-29 | 2015-03-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
| WO2011139988A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases |
| EP2566496B1 (de) | 2010-05-03 | 2018-02-28 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von methionyl-trna-synthetasen |
| ES2623805T3 (es) | 2010-05-03 | 2017-07-12 | Atyr Pharma, Inc. | Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas |
| CN103096925A (zh) | 2010-05-03 | 2013-05-08 | Atyr医药公司 | 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现 |
| CN102985103A (zh) | 2010-05-04 | 2013-03-20 | Atyr医药公司 | 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现 |
| EP2566492B1 (de) | 2010-05-04 | 2016-10-26 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer zusammensetzungen im zusammenhang mit proteinfragmenten von glutamyl-prolyl-trna-synthetasen |
| CA2799197C (en) | 2010-05-14 | 2019-10-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
| CA2799480C (en) | 2010-05-17 | 2020-12-15 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases |
| CA2800375C (en) | 2010-05-27 | 2021-03-09 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases |
| CN103118694B (zh) | 2010-06-01 | 2016-08-03 | Atyr医药公司 | 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
| AU2011289831C1 (en) | 2010-07-12 | 2017-06-15 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| WO2012021249A2 (en) | 2010-07-12 | 2012-02-16 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases |
| US8999321B2 (en) | 2010-07-12 | 2015-04-07 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases |
| KR102099730B1 (ko) | 2010-07-12 | 2020-04-16 | 에이티와이알 파마, 인코포레이티드 | 아스파르틸trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견 |
| AU2011293294B2 (en) | 2010-08-25 | 2016-03-24 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases |
| CA2812795C (en) | 2010-10-06 | 2021-08-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of tryptophanyl trna synthetases |
| US9714419B2 (en) | 2011-08-09 | 2017-07-25 | Atyr Pharma, Inc. | PEGylated tyrosyl-tRNA synthetase polypeptides |
| WO2013086216A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Improved aspartyl-trna synthetases |
| WO2013086228A1 (en) | 2011-12-06 | 2013-06-13 | Atyr Pharma, Inc. | Pegylated aspartyl-trna synthetase polypeptides |
| EP2797959A4 (de) | 2011-12-29 | 2015-08-26 | Atyr Pharma Inc | Aspartyl-trna-synthetase-fc-konjugate |
| AU2013221317B2 (en) | 2012-02-16 | 2017-07-06 | Pangu Biopharma Limited | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
| ES2847383T3 (es) | 2013-03-15 | 2021-08-03 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| KR101899591B1 (ko) * | 2015-02-26 | 2018-09-17 | 재단법인 의약바이오컨버젼스연구단 | 트립토파닐 티알엔에이 합성효소를 유효성분으로 포함하는 감염성 염증 질환의 치료 또는 예방용 조성물 및 면역증강용 조성물 |
| ES2994451T3 (en) | 2017-04-20 | 2025-01-24 | Atyr Pharma Inc | Compositions for treating lung inflammation |
| WO2023001288A1 (zh) * | 2021-07-23 | 2023-01-26 | 百奥泰生物制药股份有限公司 | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 |
| CN116515827B (zh) * | 2023-03-20 | 2024-12-10 | 复旦大学附属眼耳鼻喉科医院 | 用于治疗年龄相关性黄斑变性的活性成分、药物组合物和应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4405378A1 (de) | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| DE4415310A1 (de) | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptide |
| DE4429461A1 (de) | 1994-08-19 | 1996-02-22 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| ATE170179T1 (de) | 1994-11-02 | 1998-09-15 | Merck Patent Gmbh | Adhäsionsrezeptor-antagonisten |
| DE19516483A1 (de) | 1995-05-05 | 1996-11-07 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
| US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
| EP1586322B1 (de) * | 1996-11-05 | 2008-08-20 | The Children's Medical Center Corporation | Zusammensetzungen enthaltend Thalidomide und Dexamethason für die Behandlung von Krebs |
| US6559144B2 (en) | 1997-02-13 | 2003-05-06 | Merck Patent Gesellschaft Mit | Bicyclic amino acids |
| DE19705450A1 (de) * | 1997-02-13 | 1998-08-20 | Merck Patent Gmbh | Bicyclische aromatische Aminosäuren |
| DE19755800A1 (de) | 1997-12-16 | 1999-06-17 | Merck Patent Gmbh | Cyclopeptidderivate |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| CA2371824A1 (en) | 1999-02-20 | 2000-08-24 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | .beta.-alanine derivatives |
| DE19916837A1 (de) | 1999-04-14 | 2000-10-19 | Merck Patent Gmbh | Dibenzoazulenderivate |
| DE19932796A1 (de) | 1999-07-14 | 2001-01-18 | Merck Patent Gmbh | Diacylhydrazinderivate |
| DE19939980A1 (de) | 1999-08-24 | 2001-03-01 | Merck Patent Gmbh | Inhibitoren des Integrins alphavbeta¶3¶ |
| IL151940A0 (en) * | 2000-03-31 | 2003-04-10 | Scripps Research Inst | HUMAN AMINOACYL-tRNA SYNTHETASE POLYPETIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| CA2427334C (en) * | 2000-11-01 | 2013-06-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Methods and compositions for the treatment of diseases of the eye |
| AU2002220265A1 (en) * | 2000-11-03 | 2002-05-15 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| UA75898C2 (en) * | 2000-11-14 | 2006-06-15 | Merck Patent Gmbh | Method for prophylaxis and treatment of eye diseases using antagonist of integrin receptors |
| BR0207449A (pt) * | 2001-02-23 | 2004-04-06 | Scripps Research Inst | Polipeptìdeos derivados de triptofanil-trna sintetase úteis para regulação da angiogênese |
| IL152420A0 (en) * | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| AU2002332430A1 (en) * | 2001-07-26 | 2003-02-17 | Novartis Ag | Methods of treating neuropilin-mediated diseases |
| HRP20040406A2 (en) * | 2001-11-09 | 2005-02-28 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| NZ535100A (en) * | 2002-03-20 | 2008-04-30 | Univ Florida | RAAV vector compositions and methods for the treatment of choroidal neovascularization |
| JP2006508635A (ja) * | 2002-05-06 | 2006-03-16 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 治療用または診断用試薬を送達するためのターゲティングタンパク質 |
| AU2004268614C1 (en) * | 2003-08-27 | 2010-10-28 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| CA2551100A1 (en) * | 2003-12-23 | 2005-07-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for combined therapy of disease |
| KR101224368B1 (ko) * | 2004-06-04 | 2013-01-22 | 더 스크립스 리서치 인스티튜트 | 혈관신생 질환 치료용 조성물 및 방법 |
-
2005
- 2005-06-06 KR KR1020077000238A patent/KR101224368B1/ko not_active Expired - Fee Related
- 2005-06-06 PT PT05804888T patent/PT1765362E/pt unknown
- 2005-06-06 MX MXPA06014092A patent/MXPA06014092A/es active IP Right Grant
- 2005-06-06 PT PT120020284T patent/PT2484365E/pt unknown
- 2005-06-06 AT AT05804888T patent/ATE551060T1/de active
- 2005-06-06 ES ES05804888T patent/ES2382661T3/es not_active Expired - Lifetime
- 2005-06-06 CA CA2568750A patent/CA2568750C/en not_active Expired - Fee Related
- 2005-06-06 US US11/145,587 patent/US7528106B2/en not_active Expired - Fee Related
- 2005-06-06 ES ES12002028.4T patent/ES2439390T3/es not_active Expired - Lifetime
- 2005-06-06 ES ES12002027.6T patent/ES2450541T3/es not_active Expired - Lifetime
- 2005-06-06 JP JP2007515675A patent/JP4943324B2/ja not_active Expired - Fee Related
- 2005-06-06 EP EP05804888A patent/EP1765362B1/de not_active Expired - Lifetime
- 2005-06-06 WO PCT/US2005/019800 patent/WO2005117954A2/en not_active Ceased
- 2005-06-06 EP EP12002028.4A patent/EP2484365B1/de not_active Expired - Lifetime
- 2005-06-06 DK DK05804888.5T patent/DK1765362T3/da active
- 2005-06-06 PL PL12002028T patent/PL2484365T3/pl unknown
- 2005-06-06 EP EP12002027.6A patent/EP2484364B1/de not_active Expired - Lifetime
- 2005-06-06 DK DK12002028.4T patent/DK2484365T3/da active
- 2005-06-06 PL PL05804888T patent/PL1765362T3/pl unknown
- 2005-06-06 AU AU2005249586A patent/AU2005249586B2/en not_active Ceased
-
2009
- 2009-05-04 US US12/387,507 patent/US20090285792A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2382661T3 (es) | 2012-06-12 |
| MXPA06014092A (es) | 2007-03-15 |
| ES2439390T3 (es) | 2014-01-22 |
| PL2484365T3 (pl) | 2014-03-31 |
| KR101224368B1 (ko) | 2013-01-22 |
| CA2568750A1 (en) | 2005-12-15 |
| PT1765362E (pt) | 2012-06-04 |
| EP1765362B1 (de) | 2012-03-28 |
| AU2005249586B2 (en) | 2010-12-23 |
| DK2484365T3 (da) | 2013-12-02 |
| EP1765362A4 (de) | 2010-02-24 |
| JP4943324B2 (ja) | 2012-05-30 |
| DK1765362T3 (da) | 2012-05-14 |
| WO2005117954A3 (en) | 2006-10-12 |
| KR20070041498A (ko) | 2007-04-18 |
| EP2484364A1 (de) | 2012-08-08 |
| PT2484365E (pt) | 2013-12-12 |
| EP2484365A1 (de) | 2012-08-08 |
| PL1765362T3 (pl) | 2012-08-31 |
| CA2568750C (en) | 2014-05-27 |
| US20060003933A1 (en) | 2006-01-05 |
| EP2484365B1 (de) | 2013-10-02 |
| JP2008501718A (ja) | 2008-01-24 |
| EP1765362A2 (de) | 2007-03-28 |
| US20090285792A1 (en) | 2009-11-19 |
| WO2005117954A2 (en) | 2005-12-15 |
| AU2005249586A1 (en) | 2005-12-15 |
| US7528106B2 (en) | 2009-05-05 |
| ES2450541T3 (es) | 2014-03-25 |
| EP2484364B1 (de) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551060T1 (de) | Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen | |
| WO2005063745A3 (en) | Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof | |
| MX383644B (es) | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. | |
| LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
| DE60331537D1 (de) | Kombinationen zur behandlung von multiplem myelom | |
| MXPA05013642A (es) | Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer. | |
| BRPI0408005A (pt) | composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor | |
| EA200970953A1 (ru) | СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ | |
| ATE424208T1 (de) | Proteinkinaseinhibitoren | |
| EP1503748A4 (de) | Arzneimittel zur linderung durch taxan induzierte neurotoxizität | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| MX2007007027A (es) | Derivados piperazinilpiridina como agentes anti-obesidad. | |
| ATE419249T1 (de) | Inhibitoren von mitotischem kinesin | |
| WO2006138589A3 (en) | Opioid receptor ligands | |
| ATE477021T1 (de) | 1,3,5-triazepin-dionen zur behandlung von malaria |